First trial assessing prophylactic PCI in patients with non-flow limiting, vulnerable plaques (via IVUS) showed DECREASED cardiac events at 2 years! 0.4% vs. 3.4% in medical therapy alone group. Composite outcome of cardiac death, TV MI, TVR, 🏥 for UA
A long-waited PREVENT trial is now presented at LBCT-V #ACC2024
🇰🇷From the inception of trial to completion of trial took a decade.
✅1,606 pts with intracoronary imaging-detected “Vulnerable Plaque” randomized 1:1 to (1) Preventive PCI vs (2) OMT alone.
✅Prevent PCI significantly reduce primary composite endpoint (CV death, TV-MI, TVR, hospitalization for UA) at 2 yr. The effect of Preventive PCI was sustained up to 7 years.
✅First RCT shows that Preventive PCI is effective for non-flow limiting vulnerable atherosclerosis coronary plaque.
✅We believe that PREVENT would be one of the seminal investigations in the history of PCI.
@dukwoo_park@GreggWStone@JungMinAhn5@DFCapodanno@djc795@TheLancet
Further details:
https://t.co/R2NJ0dsdML
A long-waited PREVENT trial is now presented at LBCT-V #ACC2024
🇰🇷From the inception of trial to completion of trial took a decade.
✅1,606 pts with intracoronary imaging-detected “Vulnerable Plaque” randomized 1:1 to (1) Preventive PCI vs (2) OMT alone.
✅Prevent PCI significantly reduce primary composite endpoint (CV death, TV-MI, TVR, hospitalization for UA) at 2 yr. The effect of Preventive PCI was sustained up to 7 years.
✅First RCT shows that Preventive PCI is effective for non-flow limiting vulnerable atherosclerosis coronary plaque.
✅We believe that PREVENT would be one of the seminal investigations in the history of PCI.
@dukwoo_park@GreggWStone@JungMinAhn5@DFCapodanno@djc795@TheLancet
Further details:
https://t.co/R2NJ0dsdML
#DanGer trial: a big win, not only for excellently named clinical trials, but for evidence of mortality benefit of Impella in STEMI-cardiogenic shock, despite increased complications! #ACC24#impella
Astonishing results from the DanGer Shock Trial presented at #ACC24 and out in @NEJM today.
In patients with ST-elevation MI with cardiogenic shock, Impella reduced all-cause mortality (45.8% Impella vs. 58.5% control) at 180 days.
Some thoughts on this ground breaking trial:
The PROTECT III study focuses on a population of patients requiring prolonged mechanical circulatory support after Impella-supported HR-PCI, observing outcomes like complications and mortality, and emphasizing the need for tailored management strategies by specialized teams. https://t.co/iB1rMVmXaF
1. After high-risk PCI with Impella support, which patients get transferred to the CCU for prolonged MCS, and how do they compare with patients who don't need prolonged MCS? A 🧵on our new sub-analysis of PROTECT III in @EuroInterventio with @Babar_Basir@JWMoses and team... 1/5
Clinical characteristics and outcomes of patients requiring prolonged mechanical circulatory support after high-risk percutaneous coronary intervention via @EuroInterventio https://t.co/9oFlnlYp7I
2. PROTECT III is a multicenter study on Impella 2.5 and CP outcomes in HR-PCI in the US. In 1,237 pts undergoing MCS-supported HR-PCI, 16% had MCS support post-procedure, and more likely to be non-White, had urgent indications (ACS), ‼️ vitals, and had more complications (2/5)